RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors and Melanoma

Summary

The purpose of this study is to assess the safety and tolerability of escalating doses of RPTR-168 as a monotherapy in patients with HPV-16 E6/E7 positive tumors (HNSCC, cervical) and melanoma.

Timeline

Start

2021-05-10

Primary completion

2022-09-14

Completion

2022-10-11

Outcome

Outcome not reported

Stopped: “Development program terminated”

Drugs

Indications